Considerations for the Utility of Real-World Evidence Beyond Trial Data in Advanced NSCLC: The Case of Frontline Tyrosine Kinase Inhibitors.

Gaitonde, Priyanka; Chirikov, Viktor; Kelkar, Sneha; Liljas, Bengt

Gaitonde, Priyanka; Chirikov, Viktor; Kelkar, Sneha; Liljas, Bengt.

Afiliação

Gaitonde P; AstraZeneca, Health Economics & Payer Evidence, Gaithersburg, MD, USA.
Chirikov V; OPEN Health Evidence & Access, Bethesda, MD, USA.
Kelkar S; OPEN Health Evidence & Access, Bethesda, MD, USA.
Liljas B; AstraZeneca, Health Economics & Payer Evidence, Gaithersburg, MD, USA.

Cancer Manag Res ; 14: 3421-3435, 2022.

Article em En | MEDLINE | ID: mdl-36514307

Palavras-chave

nonsmall cell lung cancer; reimbursement; short- and long-term outcomes; time to treatment discontinuation

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Prognostic_studies Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google